Dexamethasone drug delivery system shows potential in macular oedema

Article

In persistent macular oedema, a single dexamethasone drug delivery system (DDS) treatment can significantly improve best corrected visual acuity (BCVA).

In persistent macular oedema, a single dexamethasone drug delivery system (DDS) treatment can significantly improve best corrected visual acuity (BCVA), according to a report published in the March issue of Archives of Ophthalmology.

Baruch Kuppermann of the University of California, Irvine, USA and colleagues, conducted a six-month randomized study of 315 subjects with persistent macular oedema. Each subject had a preoperative BCVA of between 20/40 and 20/200 in the study eye and were randomized to observation or a single treatment with dexamethasone DDS (350 or 700 µg).

At day 90, an improvement in BCVA of 10 letters or more was achieved by more patients in the treatment arm (700 µg: 35%; 350 µg: 24%) than in those patients in the observation arm (13%; p<0.001 vs 700 µg group; p=0.04 vs 350 µg group).

An improvement in BCVA of 15 letters or more was achieved in 18% of patients treated with dexamethasone DDS 700 µg, versus 6% of observed patients (p=0.006). During the three-month observation period, 11% of treated patients and 2% of observed patients had an intraocular pressure increase of 10 mmHg or higher.

The authors of the study believe that dexamethasone DDS (700 µg) could have potential as an effective treatment for patients with persistent macular oedema.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.